Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: From protein buffer capacity prediction to bioprocess applications

Biotechnology Journal

Volumn 10, Issue 4, 2015, Pages 610-622

  Bahrenburg, Sven ^a   Karow, Anne R ^a   Garidel, Patrick ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Clinical compatibility; Monoclonal antibody; PH buffering; Protein stability; Self buffering formulation

Indexed keywords

BUFFER STORAGE; MONOCLONAL ANTIBODIES; PROTEINS; STABILITY;

CLINICAL COMPATIBILITY; MONOCLONAL ANTIBODIES (MABS); PH BUFFERING; PROTEIN CONCENTRATIONS; PROTEIN STABILITY; SELF-BUFFERING; TEMPERATURE STABILITY; THERAPEUTIC ANTIBODIES;

ANTIBODIES;

BUFFER; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4; MONOCLONAL ANTIBODY 5; PROTEIN; UNCLASSIFIED DRUG;

ACCELERATION; ANIMAL CELL; ARTICLE; BIOENGINEERING; BIOPROCESS; CALCULATION; DRUG FORMULATION; DRUG STABILITY; FEMALE; INFUSION; ISOELECTRIC POINT; LIQUID; MAMMAL CELL; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN STABILITY; TEMPERATURE;

EID: 84964200259     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400531     Document Type: Article

References (33)

1. Ehrlich, P., Collected studies on immunity. New York: J. Wiley & Sons 1906.
2. Weiner, L.M., Surana, R., Wang, S., Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317-327.
3. Bergemann, K., Eckermann, C., Garidel, P., Grammatikos, S. et al., Production and downstream processing. In handbook of therapeutic antibodies 2007, 199-237. Wiley-VCH Verlag GmbH.
4. Karow, A.R., Bahrenburg, S., Garidel, P., Buffer capacity of biologics - from buffer salts to buffering by antibodies. Biotechnol. Prog. 2013, 480-492.
5. Gokarn, Y.R., Kras, E., Nodgaard, C., Dharmavaram, V. et al., Self-buffering antibody formulations. J. Pharm. Sci. 2008, 97, 3051-3066.
6. Schweizer, D., Schönhammer, K., Jahn, M., Göpferich, A., Protein-Polyanion Interactions for the Controlled Release of Monoclonal Antibodies. Biomacromolecules 2012, 14, 75-83.
7. Jacobi, A., Enenkel, B., Garidel, P., Eckermann, C. et al., Process development and manufacturing of therapeutic antibodies. In handbook of therapeutic antibodies 2014, 601-664. Wiley-VCH Verlag GmbH & Co. KGaA.
8. Stoner, M.R., Fischer, N., Nixon, L., Buckel, S. et al., Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations. J. Pharm. Sci. 2004, 93, 2332-2342.
9. Miao, F., Velayudhan, A., DiBella, E., Shervin, J. et al., Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody. Biotechnol. Prog. 2009, 25, 964-972.
10. Teeters, M., Bezila, D., Benner, T., Alfonso, P., Alred, P., Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies. Biotechnol. Bioeng. 2011, 108, 1338-1346.
11. Bolton, G.R., Boesch, A.W., Basha, J., Lacasse, D.P. et al., Effect of protein and solution properties on the Donnan effect during the ultrafiltration of proteins. Biotechnol. Prog. 2011, 27, 140-152.
12. Lehermayr, C., Mahler, H.C., Mäder, K., Fischer, S., Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J. Pharm. Sci. 2011, 100, 2551-2562.
13. Harinarayan, C., Skidmore, K., Kao, Y., Zydney, A.L., van Reis, R., Small molecule clearance in ultrafiltration/diafiltration in relation to protein interactions:Study of citrate binding to a Fab. Biotechnol. Bioeng. 2009, 102, 1718-1722.
14. Lide, D.R. CRC handbook of chemistry and physics, 85th edition. 2004, Taylor & Francis.
15. den Engelsman, J., Garidel, P., Smulders, R., Koll, H. et al., Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm. Res. 2011, 28, 920-933.
16. Marichal-Gallardo, P.A., Alvarez, M.M., State-of-the-art in downstream processing of monoclonal antibodies: Process trends in design and validation. Biotechnology Progress 2012, 28, 899-916.
17. Vunnum, S., Vedantham, G., Hubbard, B., Protein A-based affinity chromatography. In process scale purification of antibodies. 2009, 79-102. John Wiley & Sons, Inc.
18. Van Slyke, D.D. On the measurements of buffer values and on the relationship of buffer value to the dissociation constant of the buffer and the concentration and reaction of the buffer solution. J. Biol. Chem. 1922, 52, 525-570.
19. Kuramitsu, S., Hamaguchi, K. Analysis of the acid-base titration curve of hen lysozyme. Journal of Biochemistry 1980, 87, 1215-1219.
20. McNutt, M., Mullins, L.S., Raushel, F.M., Pace, C.N., Contribution of histidine residues to the conformational stability of ribonuclease T1 and mutant Glu-58 ? Ala. Biochemistry 1990, 29, 7572-7576.
21. Ragone, R. Hydrogen-bonding classes in proteins and their contribution to the unfolding reaction. Protein Science 2001, 10, 2075-2082.
22. Thurlkill, R.L., Grimsley, G.R., Scholtz, J.M., Pace, C.N., Hydrogen bonding markedly reduces the pK of buried carboxyl groups in proteins. Journal of Molecular Biology 2006, 362, 594-604.
23. Leem, C.H., Lagadic-Gossmann, D., Vaughan-Jones, R.D., Characterization of intracellular pH regulation in the guinea-pig ventricular myocyte. The Journal of Physiology 1999, 517, 159-180.
24. a values in proteins. Proteins: Structure, Function, and Bioinformatics 2002, 48, 388-403.
25. Tomita, M., Irie, M., Ukita, T., Sensitized photooxidation of histidine and its derivatives. Products and mechanism of the reaction. Biochemistry 1969, 8, 5149-5160.
26. Laursen, T., Hansen, B., Fisker, S., Pain perception after subcutaneous injections of media containing different buffers. Basic & Clinical Pharmacology & Toxicology 2006, 98, 218-221.
27. Yadav, S., Shire, S.J., Kalonia, D.S., Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J. Pharm. Sci. 2010, 99, 4812-4829.
28. Jezek, J., Rides, M., Derham, B., Moore, J. et al., Viscosity of concentrated therapeutic protein compositions. Advanced Drug Delivery Reviews 2011, 63, 1107-1117.
29. Borchert, S.J., Ryan, M.M., Davison, R.L., Speed, W., Accelerated extractable studies of borosilicate glass containers. Journal of parenteral science and technology : a publication of the Parenteral Drug Association 1989, 43, 67-79.
30. Preston, W.A., Anderson, N.R. Glass and rubber closure effects on the pH of water I. A preliminary investigation. Journal of Parenteral Science and Technology 1984, 38, 11-16.
31. Preston, W.A., Anderson, N.R., Glass and rubber closure effects on the pH of water II. A proposed mechanism of interaction. Journal of Parenteral Science and Technology 1985, 39, 28-47.
32. White, F., Koberda, M., Chilamkurti, R., A systematic approach for screening glass containers and elastomeric closures for use with parenteral solutions. PDA Journal of Pharmaceutical Science and Technology 2008, 62, 157-176.
33. Carpenter, J., Pikal, M., Chang, B., Randolph, T., Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res. 1997, 14, 969-975.